New evidence suggests decreased mortality could outweigh an elevated risk for hyperkalemia in patients heart failure treated ...

A new pill called baxdrostat may offer hope for people whose blood pressure stays high even after taking standard medications ...

The proportion of people with heart failure receiving optimal therapy increased significantly with expansion of this initiative within a general cardiology practice.

RemeGen has submitted a Biologics License Application (BLA) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for IgAN, which if approved would ...

Iptacopan, an oral factor B inhibitor, previously received accelerated approval in 2024 under the brand name Fabhalta for IgAN, specifically to reduce proteinuria in patients at risk of rapid disease ...

KDIGO's new IgA nephropathy guideline shifts the treatment paradigm from supportive care alone to targeting the disease's immunologic nature.

A new drug lowered blood pressure and improved kidney health markers in high-risk patients. Phase 3 trials will test its long-term effects. Preliminary research suggests that adding the new medication ...

In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1eGFR ...